[Response evaluation criteria in chemotherapy for cervix neoplasm].

Nihon Rinsho

Department of Obstetrics and Gynecology, Kitano Hospital.

Published: October 2004

Download full-text PDF

Source

Publication Analysis

Top Keywords

[response evaluation
4
evaluation criteria
4
criteria chemotherapy
4
chemotherapy cervix
4
cervix neoplasm]
4
[response
1
criteria
1
chemotherapy
1
cervix
1
neoplasm]
1

Similar Publications

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within preexisting benign lesions called plexiform neurofibromas (PNs). PNs are solely driven by biallelic loss eliciting RAS pathway activation, and they respond favorably to MEK inhibitor therapy.

View Article and Find Full Text PDF

Objective: To determine the direct and indirect effects of sexual assault on sleep health in varsity athletes.

Participants: Varsity athletes ( = 2,910) who completed the Fall 2019 or 2020 administrations of the American College Health Association's National College Health Assessment III.

Methods: We combined exploratory factor analysis and structural equation modeling to evaluate relationships between four predictor variables: and and two response variables: and

Results: Overall, 9.

View Article and Find Full Text PDF

Objective: Pleural metastasis (PM) is rare in patients with differentiated thyroid cancer (DTC). Radioiodine (131I) therapy has been the main treatment for postoperative metastasis and recurrence of DTC. However, clinical data on PM from DTC are limited.

View Article and Find Full Text PDF

Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK cell function with oncological drugs could improve NK cell-based immunotherapies. Here, we used a high-throughput drug screen consisting of over 500 small-molecule compounds to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells.

View Article and Find Full Text PDF

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!